FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021009476> ?p ?o ?g. }

• W2021009476 abstract "You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Hormonal Therapy1 Apr 2014PD23-09 ALFUZOSIN AND FLUBRIPROFEN COMBINATION THERAPY FOR THE MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS Cevdet Serkan Gokkaya, Binhan Kagan Aktas, Cuneyt Ozden, Suleyman Bulut, Mehmet Karabakan, Akif Ersoy Erkmen, and Ali Memis Cevdet Serkan GokkayaCevdet Serkan Gokkaya More articles by this author , Binhan Kagan AktasBinhan Kagan Aktas More articles by this author , Cuneyt OzdenCuneyt Ozden More articles by this author , Suleyman BulutSuleyman Bulut More articles by this author , Mehmet KarabakanMehmet Karabakan More articles by this author , Akif Ersoy ErkmenAkif Ersoy Erkmen More articles by this author , and Ali MemisAli Memis More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1846AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To compare the efficacy and safety of alfuzosin alone, flurbiprofen alone, and alfuzosin plus flurbiprofen combination for lower urinary tract symptoms (LUTS)caused by benign prostatic obstruction (BPO). METHODS Seventy-eight patients complaining of LUTS secondary to BPO were enrolled in this clinical trial. Patients without any cardiac or hepatorenal insuffenciency and without peptic ulcus history were randomly assigned to receive alfuzosin XL 10 mg, flurbiprofen SR 200mg or combination treatment. Trans-rectal ultrasound was performed for measurement of prostatic volume firstly, then patients were evaluated by using International Prostate Symptom Score (IPSS) (irritative, obstructive and total separately), uroflowmetry (maximal and average urinary flow rate (Qmax and Qave)) and both at baseline and following a 4-week treatment course. RESULTS There was not any difference among the groups regarding age and baseline values of prostate volume, irritative, obstructive and total IPSS, Qmax, Qave and residue (P >.05). The total, irritative and obstructive IPSS and residue decreased significantly in all 3 groups after treatment (P <.01). Qmax and Qave significantly improved only in combination therapy group (P <.01) without any additional significant side effect. CONCLUSIONS A combination of an alpha blocker alfuzosin with flurbiprofen which is a member of the phenylalkanoic acid derivative family of nonsteroid anti-inflammatory drugs, is superior to alfuzosin or flurbiprofen alone for the treatment of LUTS secondary to BPO regarding uroflowmetric parameters. Table 1. Alfuzosin XL 10mg (n=29) (Age: 61.4±8.9 years) (Prostate volume: 37,7±12,3 gr) Pretreatment (mean±SD) Posttreatment (mean±SD) p value Qmax (ml/sn) 14,7±6,6 15,3±5,8 0,26 Qave (ml/sn) 8,5±3,9 8,8±3,5 0,26 Residue (ml) 97,8±84,5 71,7±92,1 0,002 total IPSS 19±4,5 12,4±5,3 <0,001 obstructive ISS 12,1±4,2 8,1±3,7 <0,001 irritative IPSS 6,9±2,5 4,2±1,8 <0,001 Table 2. Flubriprofen SR 200mg (n=21) (Age: 58,8±6,2 years) (Prostate volume: 36,1±9,7 gr) Pretreatment (mean±SD) Posttreatment (mean±SD) p value Qmax (ml/sn) 15,6±6,3 16,,8±7 0,22 Qave (ml/sn) 8,9±3,7 10±3,8 0,17 Residue (ml) 81,1±86,2 45,7±25,4 0,006 total IPSS 17,3±4,8 13,4±5,4 <0,001 obstructive ISS 10,8±3,2 9±3,6 0,002 irritative IPSS 6,5±2,3 4,4±2,1 <0,001 Table 3. Combination (Alfuzosin XL 10mg + Flubriprofen SR 200mg) (n=28) (Age: 58,8±6,1 years) (Prostate volume: 35,8±11,2 gr) Pretreatment (mean±SD) Posttreatment (mean±SD) p value Qmax (ml/sn) 14±7,6 16,9±8,4 <0,001 Qave (ml/sn) 8,3±4 9,9±4,2 <0,001 Residue 95,4±80,1 59,9±47 <0,001 total IPSS 17,8±5,9 11,9±4,6 <0,001 obstructive ISS 10,4±3,7 7,4±3,4 <0,001 irritative IPSS 7,5±3,6 4,5±2,2 <0,001 © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e669-e670 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Cevdet Serkan Gokkaya More articles by this author Binhan Kagan Aktas More articles by this author Cuneyt Ozden More articles by this author Suleyman Bulut More articles by this author Mehmet Karabakan More articles by this author Akif Ersoy Erkmen More articles by this author Ali Memis More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2021009476 created "2016-06-24" @default.
• W2021009476 creator A5003071699 @default.
• W2021009476 creator A5013201810 @default.
• W2021009476 creator A5018599712 @default.
• W2021009476 creator A5022544414 @default.
• W2021009476 creator A5050863442 @default.
• W2021009476 creator A5059460162 @default.
• W2021009476 creator A5063052111 @default.
• W2021009476 date "2014-04-01" @default.
• W2021009476 modified "2023-09-28" @default.
• W2021009476 title "PD23-09 ALFUZOSIN AND FLUBRIPROFEN COMBINATION THERAPY FOR THE MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS" @default.
• W2021009476 doi "https://doi.org/10.1016/j.juro.2014.02.1846" @default.
• W2021009476 hasPublicationYear "2014" @default.
• W2021009476 type Work @default.
• W2021009476 sameAs 2021009476 @default.
• W2021009476 citedByCount "0" @default.
• W2021009476 crossrefType "journal-article" @default.
• W2021009476 hasAuthorship W2021009476A5003071699 @default.
• W2021009476 hasAuthorship W2021009476A5013201810 @default.
• W2021009476 hasAuthorship W2021009476A5018599712 @default.
• W2021009476 hasAuthorship W2021009476A5022544414 @default.
• W2021009476 hasAuthorship W2021009476A5050863442 @default.
• W2021009476 hasAuthorship W2021009476A5059460162 @default.
• W2021009476 hasAuthorship W2021009476A5063052111 @default.
• W2021009476 hasConcept C121608353 @default.
• W2021009476 hasConcept C126322002 @default.
• W2021009476 hasConcept C126894567 @default.
• W2021009476 hasConcept C2776235491 @default.
• W2021009476 hasConcept C2776547966 @default.
• W2021009476 hasConcept C2777562237 @default.
• W2021009476 hasConcept C2779478474 @default.
• W2021009476 hasConcept C2780546585 @default.
• W2021009476 hasConcept C2781000538 @default.
• W2021009476 hasConcept C42219234 @default.
• W2021009476 hasConcept C71924100 @default.
• W2021009476 hasConceptScore W2021009476C121608353 @default.
• W2021009476 hasConceptScore W2021009476C126322002 @default.
• W2021009476 hasConceptScore W2021009476C126894567 @default.
• W2021009476 hasConceptScore W2021009476C2776235491 @default.
• W2021009476 hasConceptScore W2021009476C2776547966 @default.
• W2021009476 hasConceptScore W2021009476C2777562237 @default.
• W2021009476 hasConceptScore W2021009476C2779478474 @default.
• W2021009476 hasConceptScore W2021009476C2780546585 @default.
• W2021009476 hasConceptScore W2021009476C2781000538 @default.
• W2021009476 hasConceptScore W2021009476C42219234 @default.
• W2021009476 hasConceptScore W2021009476C71924100 @default.
• W2021009476 hasIssue "4S" @default.
• W2021009476 hasLocation W20210094761 @default.
• W2021009476 hasOpenAccess W2021009476 @default.
• W2021009476 hasPrimaryLocation W20210094761 @default.
• W2021009476 hasRelatedWork W1978630268 @default.
• W2021009476 hasRelatedWork W2008129012 @default.
• W2021009476 hasRelatedWork W2013357874 @default.
• W2021009476 hasRelatedWork W2105283741 @default.
• W2021009476 hasRelatedWork W2116616598 @default.
• W2021009476 hasRelatedWork W2142133236 @default.
• W2021009476 hasRelatedWork W2330542927 @default.
• W2021009476 hasRelatedWork W3175503089 @default.
• W2021009476 hasRelatedWork W4313146201 @default.
• W2021009476 hasRelatedWork W4382462402 @default.
• W2021009476 hasVolume "191" @default.
• W2021009476 isParatext "false" @default.
• W2021009476 isRetracted "false" @default.
• W2021009476 magId "2021009476" @default.
• W2021009476 workType "article" @default.